ALKS Alkermes PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: ALKS
- PE Ratio
As at Jul 25, 2025, the ALKS stock has a PE ratio of 12.15. This is based on the current EPS of $2.15 and the stock price of $26.13 per share. A decrease of 13% has been recorded in the P/E ratio compared to the average of 14.0 of the last 4 quarters.
ALKS PE ratio history
The mean historical PE ratio of Alkermes over the last three years is 19.06. The current 12.15 PE ratio is 36% below the historical average. In the past three years, ALKS's PE ratio was at its highest in the Jun 2023 quarter at 51.31, with a price of $31.3 and an EPS of $0.61. The Mar 2024 quarter recorded the bottom point at 10.33, with a price of $27.07 and an EPS of $2.62.
Alkermes PE ratio by year
Maximum annual decrease: -0.08% in 2024
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 12.95 | -0.08% | $28.76 | $2.22 |
| 2023 | 12.96 | N/A | $27.74 | $2.14 |
| 2022 | N/A | N/A | $26.13 | -$0.97 |
| 2021 | N/A | N/A | $23.26 | -$0.3 |
| 2020 | N/A | N/A | $19.95 | -$0.7 |
| 2019 | N/A | N/A | $20.4 | -$1.25 |
| 2018 | N/A | N/A | $29.51 | -$0.9 |
| 2017 | N/A | N/A | $54.73 | -$1.03 |
| 2016 | N/A | N/A | $55.58 | -$1.38 |
| 2015 | N/A | N/A | $79.38 | -$1.52 |
| 2014 | N/A | N/A | $58.56 | -$0.21 |
| 2013 | 124.74 | N/A | $23.7 | $0.19 |
| 2012 | N/A | N/A | $18.55 | -$0.99 |
| 2011 | N/A | N/A | $12.95 | -$0.48 |
| 2010 | N/A | N/A | $12.97 | -$0.42 |
Alkermes PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2025 | 15.36 | 18.61% | $33.02 | $2.15 |
| Dec 2024 | 12.95 | -7.04% | $28.76 | $2.22 |
| Sep 2024 | 13.93 | 0% | $27.99 | $2.01 |
| Jun 2024 | 13.93 | 34.85% | $24.1 | $1.73 |
| Mar 2024 | 10.33 | -20.29% | $27.07 | $2.62 |
| Dec 2023 | 12.96 | -40.3% | $27.74 | $2.14 |
| Sep 2023 | 21.71 | -57.69% | $28.01 | $1.29 |
| Jun 2023 | 51.31 | N/A | $31.3 | $0.61 |
| Mar 2023 | N/A | N/A | $28.19 | -$1 |
| Dec 2022 | N/A | N/A | $26.13 | -$0.97 |
| Sep 2022 | N/A | N/A | $22.33 | -$0.78 |
| Jun 2022 | N/A | N/A | $29.79 | -$0.57 |
| Mar 2022 | N/A | N/A | $26.31 | -$0.38 |
| Dec 2021 | N/A | N/A | $23.26 | -$0.3 |
| Sep 2021 | N/A | N/A | $30.84 | -$0.58 |
ALKS Price vs fair value
ALKS average PE ratio chart
ALKS's current P/E ratio is lower than the 3, 5 and 10-year averages.
ALKS PE vs peers
ALKS's PE ratio is lower than its peer stocks JNJ and NVS. Alkermes is presently trading at a lower PE ratio (12.15) than its peer group average of 19.95.
| Stock name | PE ratio | Market cap |
|---|---|---|
| ALKS Alkermes plc | 12.15 | $4.31B |
| NVS Novartis AG | 17.03 | $227.86B |
| PFE Pfizer Inc | 17.83 | $140.94B |
| JNJ Johnson & Johnson | 17.89 | $405.32B |
| BMY Bristol Myers Squibb Co | 18.07 | $98.56B |
| AZN Astrazeneca plc | 28.95 | $225.25B |
| TEVA Teva Pharmaceutical Industries Ltd | N/A | $18.97B |
Frequently asked questions
What is Alkermes's PE ratio?
The price to earnings ratio for ALKS stock as of Jul 25, 2025, stands at 12.15.
What is the 3-year average PE ratio for Alkermes (ALKS)?
As an average over the last 3 years, ALKS stock has a PE ratio of 19.06.
What is the 5-year average PE ratio for Alkermes (ALKS)?
As an average over the last 5 years, ALKS stock has a PE ratio of 19.06.
What is the highest PE ratio for ALKS?
The highest quarterly PE ratio in the last three years has been 51.31 and it was in the Jun 2023 quarter.
How does the current PE ratio for ALKS compare to its historical average?
ALKS's current price to earnings ratio is 36% below its 3-year historical average.
How is ALKS's PE ratio calculated (Alkermes PE ratio formula)?
The PE ratio is calculated by dividing the most recent price of a stock by its trailing twelve months EPS. As of today (Jul 25, 2025), Alkermes's stock price is $26.13. The earnings per share for the trailing twelve months (TTM) ending Mar 2025 is $2.15. Therefore, Alkermes's P/E ratio for today is 12.15. PE RATIO(12.15) = STOCK PRICE($26.13) / TTM EPS($2.15)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.